NASDAQ:OPK - Opko Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.40 -0.01 (-0.41 %)
(As of 04/18/2019 04:00 PM ET)
Previous Close$2.41
Today's Range$2.35 - $2.44
52-Week Range$2.34 - $6.40
Volume6.73 million shs
Average Volume5.08 million shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$990.30 million
Book Value$3.06 per share

Profitability

Net Income$-153,040,000.00

Miscellaneous

Employees5,690
Market Cap$1.48 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Opko Health (NASDAQ:OPK) Frequently Asked Questions

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) posted its quarterly earnings data on Wednesday, February, 27th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $221.90 million for the quarter, compared to analysts' expectations of $242.05 million. Opko Health had a negative net margin of 15.46% and a negative return on equity of 7.69%. View Opko Health's Earnings History.

When is Opko Health's next earnings date?

Opko Health is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Opko Health.

What price target have analysts set for OPK?

2 Wall Street analysts have issued 12 month price targets for Opko Health's stock. Their forecasts range from $5.00 to $20.00. On average, they expect Opko Health's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 420.8% from the stock's current price. View Analyst Price Targets for Opko Health.

What is the consensus analysts' recommendation for Opko Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health exited the fourth quarter on a mixed note, with adjusted loss per share, narrower than expected and revenues missing estimates. The company has gained significantly from RAYALDEE contribution in the quarter. Also, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 20,000 tests registered in the fourth quarter. OPKO Health announced that the FDA has approved the company’s point-of-care Sangia Total PSA Test using the Claros 1 Analyzer. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. On the flip side, OPKO Health’s operating margins look pressed at the moment. Also, the company faces cutthroat competition in the MedTech space. Moreover, the decline in R&D expenses indicates reduced focus on innovation. Sluggishness in the Product revenue segment is an added headwind. The stock underperformed its industry in a year's time." (3/19/2019)
  • 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares but are reducing our 12-month price target to $5 from $7. Even given the reduced target, price appreciation potential remains at approximately 80%, hence our constructive rating. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the remainder of OPKO’s product pipeline." (2/28/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $20 for OPK shares post a 2Q18 EPS beat. We continue to think that the long-term sales and earnings potential of OPK’s business is underappreciated and that upward earnings revisions in 2019+ to levels not reflected in consensus expectations should drive the stock higher. We expect upward earnings revisions to come from the uptake of Rayaldee, commercialization of OPK’s branded drug pipeline, and BioReference sales growth and margin expansion." (8/7/2018)

Has Opko Health been receiving favorable news coverage?

Press coverage about OPK stock has been trending positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Opko Health earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 84,990,147 shares, an increase of 4.6% from the March 15th total of 81,261,939 shares. Based on an average daily trading volume, of 4,704,126 shares, the short-interest ratio is currently 18.1 days. Approximately 23.7% of the shares of the company are short sold. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), Bausch Health Companies (BHC), Novavax (NVAX), Celldex Therapeutics (CLDX) and AT&T (T).

Who are Opko Health's key executives?

Opko Health's management team includes the folowing people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP & CFO (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

Who are Opko Health's major shareholders?

Opko Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RK Asset Management LLC (0.19%), Huntington National Bank (0.01%), First Manhattan Co. (0.01%), Virtu Financial LLC (0.01%), CRA Financial Services LLC (0.00%) and Wedbush Securities Inc. (0.00%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Which institutional investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and CRA Financial Services LLC. View Insider Buying and Selling for Opko Health.

Which institutional investors are buying Opko Health stock?

OPK stock was bought by a variety of institutional investors in the last quarter, including RK Asset Management LLC, Huntington National Bank, Virtu Financial LLC, Wedbush Securities Inc., Mercer Global Advisors Inc. ADV and Meeder Asset Management Inc.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $2.40.

How big of a company is Opko Health?

Opko Health has a market capitalization of $1.48 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.

What is Opko Health's official website?

The official website for Opko Health is http://www.opko.com.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]


MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  754
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Featured Article: Candlestick

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel